Panretin

(alitretinoin)

Phase 3Small molecule

AAdvanz Pharma

Panretin is one of 93 small molecule programs targeting Lichen Planus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Lichen PlanusActive, not recruiting

DermatitisActive, not recruiting

PsoriasisActive, not recruiting

Cutaneous Lupus ErythematosusActive, not recruiting

Lichen PlanusPhase 2

Active, not recruiting

DermatitisPhase 3

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Cutaneous Lupus ErythematosusPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Panretin

AAdvanz Pharma

Phase 3

1 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dermatitis4 trials

Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Completed· Basilea Pharmaceutica logo

Basilea Pharmaceutica·Phase 3·NCT00309621·250 enrolled

Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

Completed· Basilea Pharmaceutica logo

Basilea Pharmaceutica·Phase 3·NCT00124436·300 enrolled

Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.

Terminated·TTechnische Universität Dresden·Phase 4·NCT01231854·15 enrolled

Show 1 more trial

Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Completed· Basilea Pharmaceutica logo

Basilea Pharmaceutica·Phase 3·NCT00124475·1,035 enrolled

Kaposi's sarcoma2 trials

A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma

Completed·AAnderson Clinical Research·N/A·NCT00002439

A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma

Completed·AAnderson Clinical Research·Phase 2·NCT00002188·27 enrolled

Chronic Hand Eczema1 trial

Alitretinoin in the Treatment of Chronic Hand Eczema

Completed· Basilea Pharmaceutica logo

Basilea Pharmaceutica·Phase 3·NCT00519675·150 enrolled

Cutaneous Lupus Erythematosus1 trial

Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

Terminated·UUniversity Hospital Muenster·Phase 2·NCT01407679·7 enrolled

Hepatic Disease1 trial

Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease

Completed·UUniversity Hospital, Gentofte, Copenhagen·Phase 1/2·NCT01261923·16 enrolled

5 more indications

Psoriasis1 trial

Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis

Completed· GSK logo

GSK·Phase 2·NCT01245140·33 enrolled

Eczema1 trial

Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema

Unknown status·UUniversity Medical Center Groningen·Phase 3·NCT03026907·116 enrolled

Lichen Planus1 trial

Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin

Unknown status·UUniversity of Zurich·Phase 2·NCT01538732·20 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Completed· GSK logo

GSK·Phase 3·NCT00817063·599 enrolled

Recurrent1 trial

Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema

Unknown status·UUniversity Medical Center Groningen·Phase 3·NCT03026946·76 enrolled

Regulatory

FDA Approval Timeline[4]

Feb 2, 1999

PANRETIN

NDA NDA020886

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for alitretinoin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — alitretinoin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for alitretinoin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020886). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Advanz Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAdvanz Pharma

Panretin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dermatitis4 trials

Kaposi's sarcoma2 trials

Chronic Hand Eczema1 trial

Cutaneous Lupus Erythematosus1 trial

Hepatic Disease1 trial

Psoriasis1 trial

Eczema1 trial

Lichen Planus1 trial

Efficacy and Safety1 trial

Recurrent1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News